Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.

Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q40409474

about

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura.Non-infectious pulmonary toxicity of rituximab: a systematic review.Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report.The late adverse events of rituximab therapy--rare but there!Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis Expanded use of rituximab in the management of non-Hodgkin lymphoma.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.Antineoplastic therapy-induced pulmonary toxicity.Management of pulmonary toxicity associated with targeted anticancer therapies.Rituximab-induced bronchiolitis obliterans organizing pneumonia.Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy.Rituximab-induced interstitial lung disease: five case reports.Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks.Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma.Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma.Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab Rituximab Induced Interstitial Lung Disease in Patients with Non-Hodgkin’s Lymphoma: A Clinical Study of Six Cases and Review of the Literature

P2860

Q26775837-526C4EDD-A83D-423F-99F5-23569AAFDE7D Q33400324-BF911AA3-D61A-4E81-B8E3-F3BD1F030396 Q34096300-6200DB8B-D2E0-4F66-951F-3D195FE70B21 Q36330730-6187C9F2-03B5-409A-9879-151711FC78E2 Q37462485-2A8010CC-65F6-4A55-BC3C-9336DF9EFC72 Q37640836-564EFED6-18E8-4D8E-A414-83328B4554E1 Q37771248-CA423406-DB5A-4E2A-AAB3-CF7658595933 Q37843939-1FE47194-A6F5-427B-A833-8941FC8C4420 Q38090724-CF6F306B-6108-42EA-A404-5E1870231FAF Q38132247-03273460-83C9-4412-AD67-7146598E72C4 Q38570532-DEA86D83-37A5-4582-94C5-0035F9B57162 Q40281058-EC57AC7A-10C9-4E1E-9CB1-AC423F7ED282 Q42181813-5B84F4EC-C2FA-4A7E-9EEF-887FF83C5231 Q43192625-172B1BCD-97B9-4925-9F81-CC2DD3EBF3A7 Q44393408-5D18140E-4260-4A5E-852B-1DC9D31A0E6E Q45392865-D68AA186-1855-4B57-8720-014CC7583367 Q46858102-EB7347D2-47B5-4735-A516-8CAE6AE5F1AA Q48616159-23A97EC6-3839-4E79-A2A3-942477AB2907 Q48857119-2F7513FF-5A4B-4A1C-8DBA-4A8C587C0EA1 Q57903178-281F2C4C-F559-4734-A4A9-0B65D814BA23 Q59048666-B463AF69-36FA-4E56-BB9C-6DB8D7CEE957

P2860

Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q40409474

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Interstitial pneumonitis durin ...... rapy for non-Hodgkin lymphoma.

@en

type

label

Interstitial pneumonitis durin ...... rapy for non-Hodgkin lymphoma.

@en

prefLabel

Interstitial pneumonitis durin ...... rapy for non-Hodgkin lymphoma.

@en

P1433

Q40409474-0F4DD948-0BD5-4246-89BE-65B5CC893380

P1476

Q40409474-4E8FC530-0D4F-4CB8-87D9-8DC6D7CA74A0

P2093

Q40409474-0254C247-88F7-4880-A929-EC66529B5EB9

Q40409474-30693B90-6340-48B0-8B8C-DE222269960C

Q40409474-3E19F019-C1EE-49C0-A678-8913793CF250

Q40409474-6A175FCA-03FE-4EC6-9912-BC9246447E2F

Q40409474-86141981-CD5C-44D6-8186-21B54610366F

Q40409474-9CD559C4-11FC-47F7-B8DD-E7ACC01F90B0

P2860

Q40409474-02E5EF49-39D9-4816-83B3-015918AFAAD5

Q40409474-04798E79-4B52-4D75-A146-D00FB394B73C

Q40409474-07B81CE2-7055-44E7-91FD-1E999F2E091C

Q40409474-0F09033C-2A4D-4B4F-A91A-098C384D578A

Q40409474-1FD791D7-8D85-403E-915D-03050436263A

Q40409474-692072E9-85EA-49F3-91B0-3EDECCE8F9B1

Q40409474-7A2136D0-6C68-417E-834D-B97A17DFB41C

Q40409474-84EC14CE-6469-4CAE-B9F3-F61FE7F46C5C

Q40409474-A5A80026-B55C-42A7-92DA-326D29F9F092

Q40409474-BE41F8FD-29D1-4677-A3D1-F0D150DC9FDB

P304

Q40409474-2426708D-C1ED-451E-BEE0-3F76694FD461

P31

Q40409474-EC9DA919-3BF7-4291-91DA-9E90886CA5DB

P356

Q40409474-8A51BDE8-A262-4A3E-A7A0-30A3F1544137

P433

Q40409474-C0F185D6-7E84-494A-AD19-302A40A8A228

P478

Q40409474-52CC203D-A4ED-4405-93E0-7B3A5C9108B0

P577

Q40409474-695E8D93-D745-43EB-8DE7-9EB52DA4CF7D

P698

Q40409474-8EC0F6AF-630B-426B-86B3-CF622F75AF5C

P921

Q40409474-5E3314C8-40C7-47C7-B695-D9A88A24CCC0

P356

10428190802270886

P1433

Leukemia & Lymphoma

P1476

Interstitial pneumonitis durin ...... rapy for non-Hodgkin lymphoma.

@en

P2093

Bi-Yun Wang

http://www.w3.org/2001/XMLSchema#string

Junning Cao

http://www.w3.org/2001/XMLSchema#string

Xiao-Nan Hong

http://www.w3.org/2001/XMLSchema#string

Xin Liu

http://www.w3.org/2001/XMLSchema#string

Ya-Jia Gu

http://www.w3.org/2001/XMLSchema#string

Zhi-Guo Luo

http://www.w3.org/2001/XMLSchema#string

P2860

Soluble TNF mediates the transition from pulmonary inflammation to fibrosis

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Lung toxicity associated with cyclophosphamide use. Two distinct patterns.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Interstitial lung disease associated with drug therapy.

Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma.

Fatal interstitial pneumonitis related to rituximab-containing regimen.

Rituximab-induced interstitial lung disease.

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

P304

1778-1783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190802270886

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18798110

http://www.w3.org/2001/XMLSchema#string

P921